In agreement with our transcriptomic studies we found that, despite the levels of CD79A remained unchanged after treatment, EC-7072 significantly decreased CD79B and IgM CLL cell surface expression (Supplementary Figure 8). This evidence concerns the gene CD79A and B-cell chronic lymphocytic leukemia.